Systematic Identification of Minor Histocompatibility Antigens Informs Outcomes after Allogeneic Stem Cell Transplantation

This study cohort is composed of 287 patients affected by myeloid disease (AML/MDS) who were subjected to allogeneic hematopoietic cell transplantation (allo-HCT) from an HLA-matched related donor. For each study subject, we have collected genomic DNA from both donor and recipient (D-R). Resulting germline whole exome sequencing from D-R pairs has formed the basis for applying an analytical pipeline to systematically predict minor histocompatibility antigens (mHAgs) ]]>
Patients included in the study were affected by myeloid disease (AML/MDS) and subjected to allogeneic hematopoietic stem cell transplantation (allo-HCT) from an HLA-matched donor. Three different cohorts of patients are included: DFCI-AML-MRD cohort: 220 donor-recipient pairs. It includes only HLA-matched familiar donor transplants performed at Dana-Farber Cancer Institute, Boston. No second transplants were included. HP-AML-MRD cohort: 58 donor-recipient pairs. It includes only HLA-matched familiar donor transplants performed at Hospital de la Princesa, Madrid. No second transplants were included. DFCI-AML training dataset: 9 patients and 11 donors. It includes patients that underwent either matched-related or matched-unrelated transplants at Dana-Farber Cancer Institute. Two patients were subjected to a second transplant from a different donor: for such patients samples from both donors are included. ]]>